Today’s update from Plus500, the Israel-based Contracts for Difference broker whose takeover by Playtech collapsed on unspecified regulatory hurdles, appears to contain one bit of very good news.
The Group is not subject to restrictions imposed by any of its regulators.
But what does it mean? Read more
Frankly, we’re sick of this. You are too, most likely. None of us wants to spend another day being strafed by rumour, counter rumour and unguided speculation about tobacco M&A. We’ve slogged through too many balance-of-probabilities analyses. We’ve had more than our fill of noncommittal steers during conversations with unattributable people familiar with things. It’s been going on for three solid months, and that’s enough. Consider this an intervention.
The Imperial Tobacco bid theory will follow after the RAW disclaimer. Read the disclaimer.
This should’ve been easy. Read more
XenoPort, a US small-cap drug maker and former GlaxoSmithKline partner, is a rumoured takeover target for sector peer Supernus Pharmaceuticals.
According to usually reliable people, Supernus has put an offer on the table of around $7.40 per share for XenoPort, which would value the latter at $470m. Takeover speculation has already lifted XenoPort by 18 per cent in the past week, taking its gain over the past month to 40 per cent after the company effectively put itself up for sale. Read more
It appears that Li Hejun, chairman and majority shareholder of Hanergy Thin Film Power, spent his morning at the opening ceremony for the Hanergy “clean energy expo centre” in Beijing. For verification, Hanergy’s press office sent this photo of Mr Li (centre) with some unidentified people from the Chinese Academy of Sciences.
Rumours are reaching FT Alphaville that nTelos, a US regional wireless company, is a takeover target for Shenandoah Telecommunications.
Shenandoah (better known as Shentel) has been putting together a knockout $200m offer for the Virginia-based mobile broadband provider, a nearly 50 per cent premium to Tuesday’s closing value, according to people claiming direct knowledge of the negotiations. A price of around $9.25 a share has been all but agreed, they said, against Tuesday’s close of $6.20. Read more
There are times when the hoax is so elaborate, you have to look beyond the attempted deception and admire the handiwork.
Cold feet or negotiation tactic? No one knows. And the people prepared to guess were 25 per cent wrong about Shire’s price this time yesterday, so their views should be taken with a degree of caution.
Nevertheless, here are the basics on the potential collapse of Abbvie’s $54bn takeover of the UK drugmaker.
No — we don’t yet have the prospectus for The People’s Operator, a mobile firm that has announced plans to list on Aim with a reported market value of more than £100m. But we do have its most recent accounts, which make it possible to back engineer what the prospectus might say. Read more
For disappointment, dashed hopes, false dawns, broken promises, under-delivery and consistently dolorous failure, there’s little to match Aim. London’s junior market has proved time and again to be a money pit. Read more
Doing the rounds on Twitter this afternoon ….
The important word there is “sportsbook”.
Betfair’s exchange has become a much-watched sentiment indicator for the Scottish vote. This is where gamblers bet against each other directly and the house extracts a rake for providing the market. At pixel time, £8.8m has been matched on the punter-to-punter exchange. Read more
Fans of schadenfreude may enjoy the following press release from Barclays, dated February 26, 2013, to publicise that …
Barclays LX now #2 US dark pool
LX is what Eric Schneiderman, the US state attorney-general, describes as a “dark pool full of predators – there at Barclays’ invitation”. His lawsuit alleges that Barclays was putting high-frequency traders in front of institutional investors, while sending bumf to the institutions that claimed the HFTs were being weeded out. Read more
We believe an AGN bid for SHPG is imminent and more attractive than VRX’s proposal.
So says John T. Boris, a managing director at SunTrust Robinson Humphrey. His is not a new idea. Shire has long been seen the obvious poison pill for Allergan, the Botox maker, which could use more bulk to fight off a $53bn hostile approach from Valeant. Read more
That’s JP Morgan Cazenove repeating its 290p target on Just Eat, a fast food delivery website it co-floated in April for 260p apiece.
Wait … what’s that about a correction? Read more
The nationalistic bluster around AstraPfizica remains blustery. Here, for example, is London Mayor Boris Johnson:
It would be very important to establish that Pfizer is genuinely committed to R&D in this country. I believe in principle that we should have an open system of markets in this country, but when I look at something like AstraZeneca and I look at an organization of that scale, of its relative importance to the UK economy, the sheer percentage of its money that goes into R&D, I think it is of great importance to Britain.
With that in mind, it’s worth taking a closer look at the experimental drug pipeline AstraZeneca has highlighted in its defence statement. These are the drugs that management expects to deliver an incremental $19bn of sales from 2017 to 2023, equivalent to 10 per cent revenue growth per annum: Read more
At pixel time we still await Blinkx’s official response to allegations of questionable practices made by Benjamin Edelman, an associate professor at Harvard Business School and a self-proclaimed sheriff of the internet advertising industry. Blinkx shares traded down as much as 51.6 per cent on the claims, knocking about £400m off its market value.
What we do have is a note from Citigroup, Blinkx’s joint house broker. In the interests of market stability we repeat it in full below, albeit with minimal fisking. Read more
What’s been lighting a fire under Forest Laboratories?
Bloomberg News prides itself on market-moving scoops. Today its reporters excelled themselves, getting Citigroup’s Q3 earnings out a full 29 minutes before they were due.
Blackberry’s logo (below) resembles nothing as much as a hail of seven silver bullets. It appears the gun has been pointing the wrong way.
Today marked the rarest of events: a Vodafone statement that directly references its joint venture partner.
The last time we had a mention of Verizon Communications outside the boilerplate on a Vodafone stock market announcement was back in 2007, when Arun Sarin was bounced (by this blog) into denying the existence of Project Vulture. It seems that Verizon, like Lord Voldemort, shall not be named. Read more
Friday afternoon RAW klaxon. Buyer beware. Usual wealth warnings apply.
Hello to the City’s new watchdog, the Financial Conduct Authority. It may seem rude to make requests on your first working day but there’s a market rumour on which we would like some clarity. It involves what would be the biggest M&A deal ever, and it’s on your patch. Read more
Swedish oil company Lundin Petroleum declined to comment on rumours that it has been in talks to sell a significant equity stake to China Petrochemicals Corporation. Read more
So the LSE had a technical b0rk this morning, which clogged the Regulatory News Service out for more than 90 minutes. The silo of corporate news was finally released at 8:37am.
No harm done though, right? Market integrity intact? Possibly not. Read more
Does US-listed Pacific Drilling look like a credible takeover target? We think it probably does, 0n balance, and we’d very much like to find out more. Read more
Paging Dr Mike Lynch. Your patient seems to be suffering some nasty post-op complications.
From Hewlett-Packard’s fourth-quarter results:
Fourth quarter and full year fiscal 2012 results include a non-cash goodwill and intangible asset impairment charge of $8.8 billion relating to the Autonomy business within the Software segment.